We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Main Sales Markets: Western Europe,Eastern Europe,Asia
Sample Provided: no
Shanghai Linzyme Biosciences Ltd.Deoxyribonuclease I - Shanghai Linzyme Biosciences Ltd.
Source: Bovine Pancrease EC: 3.1.21.1
DESCRIPTION
Bovine pancreatic deoxyribonuclease (DNase) is an endonuclease which splits phosphodiester linkages, preferentially adjacent to a pyrimidine nucleotide yielding polynucleotides with free hydroxyl group at the 3' position and phosphate group at the 5' position. The optimum pH is 7.8. DNase I is activated by bivalent metals, and inhibited by chelating agents such EDTA and sodium dodecyl sulfate. DNase I can be stabilized against proteolytic digestion by 5 mM Ca2+.
Linzyme Deoxyribonuclease has been chromatographically purified to remove trace contaminating proteases. DNase may be used in clinic to thin and liquefy mucus in the lungs.
SPECIFICATION (I)
Item
Specifications
Methods
Appearance
White or pale yellow lyophilized powder
Activity
≥ 3,000 Christensen units/mg powder
K.P.
Loss on drying
≤ 0.3%
K.P.
Residue on ignition
≤ 1.0%
K.P.
Conclusion: Product complies with KP.
SPECIFICATION (II)
Activity
≥ 500 Kunitz units/mg powder
Sigma-aldrich
SPECIFICATION (III)
Activity
≥ 2,000 Kunitz units/mg powder
Sigma-aldrich
STORAGE Store in an airtight container, at a temperature of 2°C to 8°C.
Fourteen years of qualification
Audited Supplier
Pharma Sources Insight JANUARY 2024
